Publicacións nas que colabora con Joaquín Díaz Mediavilla (8)

2012

  1. Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease

    Haematologica, Vol. 97, Núm. 4, pp. 616-621

  2. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

    Blood, Vol. 119, Núm. 3, pp. 687-691

  3. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: A randomized phase 3 PETHEMA/GEM study

    Blood, Vol. 120, Núm. 8, pp. 1589-1596

2010

  1. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study

    Haematologica, Vol. 95, Núm. 11, pp. 1913-1920

2008

  1. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma

    Blood, Vol. 112, Núm. 9, pp. 3591-3593

2006

  1. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase 1/2 study

    Blood, Vol. 108, Núm. 7, pp. 2165-2172

2000

  1. Are myeloma patients with renal failure candidates for autologous stem cell transplantation?

    Hematology Journal, Vol. 1, Núm. 1, pp. 28-36

  2. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: A comparative study of efficacy and toxicity from the Spanish Registry for transplantation in multiple myeloma

    British Journal of Haematology, Vol. 109, Núm. 1, pp. 138-147